Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods.
Explore the source record for details and available documents.
Adenocarcinoma↗
Biomedical subjects
N J Talley
Publications and source records attributed to N J Talley.
The effects of lottery incentive and length of questionnaire on health survey response rates: a randomized study.
Maximizing the response rate of self-administered questionnaires is key in survey research. We aimed to evaluate the effects of lottery incentive and length of questionnaire on health survey response rates when used in isolation or combined. A random sample of 440 residents in Western Sydney, Australia was randomly allocated to four equal groups to receive or not receive an instant lottery ticket and a long (seven page) or short (one page) questionnaire. The overall response rate was 71.8%. The final response rates were higher among those receiving the short, rather than the long, questionnaire (75.6% versus 68.2%) (P = 0.08); and among those receiving the lottery incentive compared with those not receiving the incentive (75% versus 68.2%) (P = 0.09). By logistic regression analysis, the success of obtaining a completed questionnaire without any follow-up reminders was significantly associated with the lottery incentive but not the questionnaire length (P = 0.03 and P = 0.54, respectively). The difference between lottery and no lottery groups decreased gradually during the follow-up. A lottery incentive is associated with an increased response after the first mailing. A small up-front cost for a lottery ticket may be worthwhile, since it can save further costs by obviating the need for repeated follow-ups.
Australia↗
Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index.
BACKGROUND: There is not at present a suitable disease-specific health-related quality of life instrument for uninvestigated dyspepsia and functional (non-ulcer) dyspepsia. AIM: To develop a new multi-dimensional disease-specific instrument. METHODS: The Nepean Dyspepsia Index (NDI) was designed to measure impairment of a subject's ability to engage in relevant aspects of their life and also their enjoyment of these aspects; in addition, the individual importance of each aspect is assessed. A 42-item quality of life measure was developed and tested, both in out-patients presenting to general practice with upper gastrointestinal complaints (n = 113) and in a randomly chosen population-based sample (n = 347). RESULTS: Adequate face and content validity was documented by an expert panel. Factor analysis identified four clinically relevant subscales: interference with activities of daily living, work, enjoyment of life and emotional well-being; lack of knowledge and control over the illness; disturbance to eating or drinking; and disturbance to sleep because of dyspepsia. These scales had high internal consistency. Both symptoms and the quality of life scores discriminated dyspepsia from health. CONCLUSION: The Nepean Dyspepsia Index is a reliable and valid disease-specific index for dyspepsia, measuring symptoms and health-related quality of life.
Adult↗
Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998.
BACKGROUND: The management of dyspepsia is controversial. METHODS: An international Working Party was convened in 1998 to review management strategies for dyspepsia and functional dyspepsia, based on a review of the literature and best clinical practice. RESULTS: Dyspepsia, defined as pain or discomfort centred in the upper abdomen, can be managed with reassurance and over-the-counter therapy if its duration is less than 4 weeks on initial presentation. For patients with chronic symptoms, clinical evaluation depends on alarm features including patient age. The age cut off selected should depend on the age specific incidence when gastric cancer begins to increase, but in Western nations 50 years is generally an acceptable age threshold. In younger patients without alarm features, Helicobacter pylori test and treatment is the approach recommended because of its value in eliminating the peptic ulcer disease diathesis. If, after eradication of H. pylori, symptoms either are not relieved or rapidly recur, then an empirical trial of therapy is recommended. Similarly, in H. pylori-negative patients without alarm features, an empirical trial (with antisecretory or prokinetic therapy depending on the predominant symptom) for up to 8 weeks is recommended. If drugs fail, endoscopy should be considered because of its reassurance value although the yield will be low. In older patients or those with alarm features, prompt endoscopy is recommended. If endoscopy is non-diagnostic, gastric biopsies are recommended to document H. pylori status unless already known. While treatment of H. pylori is unlikely to relieve the symptoms of functional dyspepsia, the long-term benefits probably outweigh the risks and treatment can be considered on a case-by-case basis. In H. pylori-negative patients with documented functional dyspepsia, antisecretory or prokinetic therapy, depending on the predominant symptom, is reasonable, assuming reassurance and explanation are insufficient, unless patients have already failed this approach. Other treatment options include antidepressants, antispasmodics, visceral analgesics such as serotonin type 3 receptor antagonists, and behavioural or psychotherapy although these are all of uncertain efficacy. Long-term drug treatment in functional dyspepsia should be avoided; intermittent short courses of treatment as needed is preferred. CONCLUSION: The management of dyspepsia recommended is based on current best evidence but must be tailored to local factors such as practice setting, the background prevalence of H. pylori and structural disease, and costs.
Decision Trees↗
Irritable bowel syndrome: definition, diagnosis and epidemiology.
Based on clinical studies, the Rome Criteria for the irritable bowel syndrome (IBS) were developed by consensus. The criteria emphasize the presence of abdominal pain and the link between pain and changes in bowel habit. The reliance on a clinical gold standard rather than a biological marker remains one of the major limitations in refining diagnostic criteria. A convincing argument can be mounted that IBS is a disease (a cause of unease). Approximately 10-15% of the general population have IBS, and it affects females more often than males, for unexplained reasons. The annual incidence is probably 1-2%. The onset of symptoms is balanced by symptom loss, so the prevalence remains stable from year to year. Up to one half have symptom improvement over time. Only a minority present for medical care; pain severity as well as psychological distress in part explain health-care seeking. IBS significantly impacts on quality of life. The economic impact is enormous, representing a multi-billion dollar problem in the United States. The development of acceptable, symptom-based diagnostic criteria has advanced the field, stimulating interest in the pathophysiology and targeted pharmacological therapy, which are essential steps if the disease burden is to be reduced.
Colonic Diseases, Functional↗
Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study.
BACKGROUND: The impact of response to treatment on subsequent symptoms, quality of life, health care consumption, and absence from work in functional dyspepsia is unknown. METHODS: Patients with functional dyspepsia from Denmark, France, Germany, The Netherlands, Hungary, and Poland (n = 567 (215 men), 18-80 years old) were followed up for 3 months after a 4-week treatment trial with omeprazole (20 mg or 10 mg) or placebo. The patients were blinded to the initial treatment. Dyspeptic symptoms and quality of life were assessed, and dyspepsia-related costs were calculated in terms of number of clinic visits, days on medication, and absence from work. RESULTS: Responders had fewer clinic visits than non-responders (1.5 versus 2.0 mean visits) and fewer days on medication (mean, 9 days versus 23 days) over the 3-month period (both, P < 0.001). The quality of life in responders was better at study entry and persisted over 3 months (all, P < 0.001). When analysed country by country, health care costs due to clinic visits and medications were significantly lower in responders in all countries (P < 0.05), except Denmark and The Netherlands. CONCLUSION: Symptom resolution in patients with functional dyspepsia has a positive impact on quality of life and reduces the subsequent costs over a 3-month period after cessation of initial treatment.
Absenteeism↗
Nonulcer dyspepsia.
Nonulcer dyspepsia, characterized by unexplained persistent or recurrent epigastric pain or discomfort, affects approximately 20% of the general population. Symptom-based diagnostic criteria, first developed by an international group of experts, have been refined in the past year in an effort to increase the applicability of the criteria (Rome II criteria). New disease-specific questionnaires that were developed to measure quality of life in patients with dyspepsia are now available and are expected to be widely used in clinical research studies. Studies on the pathophysiology and management of nonulcer dyspepsia were other major topics in the past year, including three large, well-conducted randomized controlled trials of Helicobacter pylori eradication and symptom resolution.
Journal Article↗
Does fear of serious disease predict consulting behaviour amongst patients with dyspepsia in general practice?
BACKGROUND: There have been relatively few studies of health care utilization amongst patients with upper gastrointestinal (GI) complaints. We postulated that health care utilization amongst patients with dyspepsia is primarily driven by fear of serious disease. METHOD: Consecutive patients presenting to primary care with dyspepsia were questioned about their health care utilization over a 12-month pre-consultation period. The patients completed a questionnaire which included validated measures of GI symptoms (including symptom frequency, duration and severity), and the shortened neuroticism scale of the Eysenck Personality Questionnaire. In total, 614 patients were recruited into the study, and 596 patients provided details of their health care utilization. Previous health care utilization was defined as one or more primary care visits for upper GI symptoms in the 12 months prior to the index visit; frequent health care utilization was defined as six or more visits over the same period. RESULTS: Previous health care utilization was reported by 80% of patients, while frequent health care utilization was reported by 26% of patients. Fear of serious illness and fear of cancer were univariately associated with previous and frequent health care utilization (both P = 0.001). However, the only independent predictors of previous health care utilization were frequent dyspepsia (odds ratio (OR) = 2.17), pain-related anxiety (OR = 2.08-4.66) and higher neuroticism scores (OR = 1.12); independent predictors of frequent health care utilization were frequent dyspepsia (OR = 3.25), pain-related anxiety (OR = 1.74-6.08), female gender (OR = 1.73) and being a non-drinker (OR = 1.72). Health care utilization was not independently associated with symptom severity or duration, or with patients' characteristics, such as age, marital status, ethnicity, smoking status or the use of non-steroidal antiinflammatory drugs. CONCLUSIONS: Consulting behaviour amongst patients with dyspepsia is driven in part by psychological factors and, in particular, by symptom-related anxiety as well as by the frequency of dyspepsia, but not primarily by fear of serious disease. Anxiety may help sustain health care utilization once the behaviour has been established.
Alcohol Drinking↗
Prevalence of combined fecal and urinary incontinence: a community-based study.
OBJECTIVE: To assess the prevalence of combined fecal and urinary incontinence. DESIGN: A cross-sectional, community-based study. SETTING: Olmsted County, Minnesota. PARTICIPANTS: Men (n = 778) and women (n = 762), aged 50 years or older, selected randomly from the population. MEASUREMENTS: Participants completed a previously validated self-administered questionnaire that assessed the occurrence of fecal and urinary incontinence in the previous year. RESULTS: The age-adjusted prevalence of incontinence was 11.1% (95% Confidence Interval (CI), 8.8-13.5) in men and 15.2% (95% CI, 12.5-17.9) in women for fecal incontinence; 25.6% (95% CI, 22.5-28.8) in men and 48.4% (95% CI, 44.7-52.2) in women for urinary incontinence; and 5.9% (95% CI, 4.1-7.6) in men and 9.4% (95% CI, 7.1-11.6) in women for combined urinary and fecal incontinence. The prevalence of fecal incontinence increased with age in men but not in women, from 8.4% among men in their fifties to 18.2% among men in their eighties (P for trend = .001). For women, the prevalence increased from 13.1% among 50-year-old women to 20.7% among women 80 years or older (P for trend = .5). Among persons with fecal incontinence, the prevalence of concurrent urinary incontinence was 51.1% among men and 59.6% among women (P = .001 and P = .003, respectively). Cross-sectionally, the age-adjusted, relative odds of fecal incontinence among persons with urinary incontinence was greater in men than in women (Odds Ratio (OR) = 3.0; 95% CI, 1.9-4.8 in men and OR = 1.8; 95% CI, 1.2-2.7 in women, P = .04). CONCLUSIONS: These findings suggest that persons with one form of incontinence are likely to have the other form as well. Despite the higher prevalence of urinary and fecal incontinence among women, the association between fecal incontinence and urinary incontinence was stronger among men than women. This finding, and the significant association between fecal incontinence and age observed in men but not in women, suggest that the etiologies may be more closely linked in men than in women.
Age Distribution↗
Barrett's esophagus: the long and the short of it.
Specialized intestinal epithelium occurs more frequently at the gastroesophageal junction than previously anticipated. It can occur either within tongues of mucosa (short segment Barrett's) or just beneath a normal z-line (intestinal metaplasia at the gastroesophageal junction). Whether the etiopathogenesis and the natural history of these two conditions are the same is as yet unclear. The role of gastroesophageal reflux disease (GERD), Helicobacter pylori, and inflammation at the gastroesophageal junction in the pathogenesis of short segment Barrett's and intestinal metaplasia at the gastroesophageal junction needs to be carefully documented. Intestinal metaplasia at the gastroesophageal junction, short segment Barrett's, and Barrett's may represent a continuum of the same disease process. Recent evidence suggests, however, that short segment Barrett's shares similar characteristics with Barrett's but may be distinct from intestinal metaplasia at the gastroesophageal junction. It is conceivable that short segment Barrett's may remain steady or even regress if and when the noxious influence wanes but, with continuing stimulation, short segment Barrett's may lengthen further to become what we observe to be Barrett's. If correct, endogenous or exogenous factors that induce progression need to be identified. Acid and bile reflux and H. pylori are possible candidates acting either singly or synergistically. Finally, the true neoplastic potential of short segment Barrett's needs clarification.
Barrett Esophagus↗
Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis.
OBJECTIVE: As conflicting studies have recently been published, we aimed to determine if Helicobacter pylori (H. pylori) infection is associated with gastric adenocarcinoma. METHODS: This was a meta-analysis of observational epidemiological studies. RESULTS: A total of 42 studies met the selection criteria and were categorized by the type of study design: eight cohort and 34 case-control studies. The pooled odds ratio for H. pylori in relation to gastric carcinoma was 2.04 (95% CI: 1.69-2.45). Both patient age (OR 0.77, 95% CI: 0.68-0.89) and intestinal type cancers (OR 1.14, 95% CI: 1.05-1.25) were independent effect modifiers. Analysis of other effect modifiers showed no relationship with female gender (OR 0.76, 95% CI: 0.64-0.89), stage of cancer (advanced %) (OR 1.12, 95% CI: 0.88-1.43), anatomical location (cardia %) (OR 1.54, 95% CI: 0.32-7.39) or cohort (nested case-control) studies (OR 1.72, 95% CI: 0.32-9.17). There was significant heterogeneity among the studies (tau2 = 149; p < 0.001). The quality of the studies varied considerably, with the majority of excellent studies producing positive results and the very poor to moderate studies producing mixed results. CONCLUSIONS: H. pylori infection is associated with a 2-fold increased risk of developing gastric adenocarcinoma.
Adenocarcinoma↗
Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index.
OBJECTIVE: The lack of a suitable disease-specific, health-related quality of life instrument for dyspepsia prompted the development of the Nepean Dyspepsia Index (NDI). The utility of the NDI in functional dyspepsia is unknown. We aimed to assess the validity of this new quality of life instrument for the first time in United States patients with documented functional dyspepsia. METHODS: The long form of the NDI contains a symptom index and 42 items designed to measure impairment of subjects' ability to engage in and to enjoy relevant aspects of their life because of dyspepsia, as well as a ranking of the individual importance of each aspect. Patients (n = 101, mean age 51 yr, 62% female) who had a history of functional dyspepsia for > or = 1 month and a negative endoscopy within the prior 1 yr were followed for 14 days. Patients completed the NDI and the validated Speilberger State-Trait Anxiety Inventory, Beck Depression Inventory, Short Form-36, and a global assessment of symptoms and quality of life at baseline and 14 days later; the NDI was also retested at 48 h and 2 wk. RESULTS: Five clinically relevant factors (subscales), namely, tension/sleep, interference, eating/drinking, knowledge/control, and work/study were identified by factor analysis, after incorporating individual importance ratings (25 items total). All subscales had excellent face validity and internal consistency (Chronbach's alpha, all >0.85). Reliability was also excellent (intraclass correlations all >0.84). There were modest typically negative correlations between a number of the NDI subscales and the Short Form-36, anxiety, and depression, indicating that the NDI is disease-specific and supporting its validity. Changes in NDI scales correlated moderately with global assessment of change (total score r = -0.49), indicating initial responsiveness. CONCLUSIONS: The Nepean Dyspepsia Index is a valid, disease-specific index for functional dyspepsia, measuring symptoms and health-related quality of life.
Dyspepsia↗
How should Helicobacter pylori positive dyspeptic patients be managed?
Dyspepsia, according to the internationally accepted Rome criteria, refers to pain or discomfort centred in the upper abdomen; patients with predominant heartburn are excluded from this group, although minor or infrequent heartburn is commonly associated with dyspepsia. It is an important condition not only because it is common and costly, but because it may indicate the presence of serious disease such as peptic ulcer or gastric cancer. However, the most frequent causes of dyspepsia are functional dyspepsia and gastro-oesophageal reflux disease. The discovery of Helicobacter pylori has resulted in important advances in the management of dyspepsia. The clinician faced with a patient who has persistent or recurrent dyspepsia needs to differentiate clearly those patients who have not been previously investigated from patients documented to have functional dyspepsia after investigation (fig 1). Here, the management of H pylori positive dyspeptic patients who have and have not been fully investigated will be reviewed.
Dyspepsia↗
Functional gastroduodenal disorders.
While widely used in research, the 1991 Rome criteria for the gastroduodenal disorders, especially symptom subgroups in dyspepsia, remain contentious. After a comprehensive literature search, a consensus-based approach was applied, supplemented by input from international experts who reviewed the report. Three functional gastroduodenal disorders are defined. Functional dyspepsia is persistent or recurrent pain or discomfort centered in the upper abdomen; evidence of organic disease likely to explain the symptoms is absent, including at upper endoscopy. Discomfort refers to a subjective, negative feeling that may be characterized by or associated with a number of non-painful symptoms including upper abdominal fullness, early satiety, bloating, or nausea. A dyspepsia subgroup classification is proposed for research purposes, based on the predominant (most bothersome) symptom: (a) ulcer-like dyspepsia when pain (from mild to severe) is the predominant symptom, and (b) dysmotility-like dyspepsia when discomfort (not pain) is the predominant symptom. This classification is supported by recent evidence suggesting that predominant symptoms, but not symptom clusters, identify subgroups with distinct underlying pathophysiological disturbances and responses to treatment. Aerophagia is an unusual complaint characterized by air swallowing that is objectively observed and troublesome repetitive belching. Functional vomiting refers to frequent episodes of recurrent vomiting that is not self-induced nor medication induced, and occurs in the absence of eating disorders, major psychiatric diseases, abnormalities in the gut or central nervous system, or metabolic diseases that can explain the symptom. The current classification requires careful validation but the criteria should be of value in future research.
Aerophagy↗
Design of treatment trials for functional gastrointestinal disorders.
Until recently many clinical trials of functional gastrointestinal disorders (FGIDs) suffered from important weaknesses in trial design, study execution, and data analysis. This makes it difficult to determine whether truly efficacious therapies exist for these disorders. One of the important methodologic problems is the absence of validated outcome measures and lack of consensus among stakeholders on how to measure outcome. Currently much of the effort is being put into the development of validated outcome measures for several of the FGIDs. The randomized, controlled trial with parallel groups is the design of choice. In this report, guidelines are given for the basic architecture of intervention studies of FGIDs. Further studies on design issues are required to ensure the recommendations will become evidence based in the future.
Cross-Over Studies↗
Helicobacter pylori eradication in patients with non-ulcer dyspepsia.
Epidemiological and pathophysiological studies, as well as clinical trials, attempting to identify a relationship between Helicobacter pylori infection and non-ulcer dyspepsia (NUD), or a subset of NUD, have produced inconsistent and confusing results. While it is possible that H. pylori eradication may be beneficial for symptom relief in a small proportion of patients, routine H. pylori testing and treatment in documented NUD is not currently widely accepted. Despite the lack of convincing evidence, the European Helicobacter pylori Study Group, an Asian Pacific Consensus Meeting, the American Digestive Health Foundation and the American Gastroenterology Association have all recommended considering H. pylori eradication in patients with NUD on a patient-by-patient basis. Recently, large prospective, randomised, double-blind, controlled clinical trials applying highly effective antimicrobial therapy have been conducted with 12 months follow-up. Although these well-designed studies have reached differing conclusions, the results have been largely negative. H. pylori eradication therapy in NUD will fail to relieve symptoms in most patients in the long term.
Child↗
Management of dyspepsia and functional dyspepsia: an international perspective.
Explore the source record for details and available documents.
Diagnosis, Differential↗
Comparison between McCoy cell line and HeLa cell line for detecting Helicobacter pylori cytotoxicity: clinical and pathological relevance.
BACKGROUND: Cell culture assay is an accurate test for detecting Helicobacter pylori cytotoxicity. AIMS: To evaluate McCoy cells for detecting Helicobacter pylori cytotoxicity by comparing with HeLa cells, and determine the association of cytotoxic strains with endoscopic and histological findings. METHODS: Helicobacter pylori isolates from 68 dyspeptic patients and 11 asymptomatic volunteers were tested. 180 microl (1.8 x 10(4) cells) of grown McCoy or HeLa cell suspension was seeded into each well of a 96-well microtitre tray and the medium was replaced once after 24 hours. Sonicate (20 microl) of each isolate was then added to the wells, in duplicate. After 24 and 48 hours incubation, intracellular vacuolation was assessed by inverted light microscopy. RESULTS: Using McCoy cells 57% of isolates showed cytotoxicity (23% weak and 34% strong), while using HeLa cells 30% of isolates showed strong cytotoxicity. All isolates toxic in HeLa cells were also toxic in McCoy cells. The prevalence of cytotoxic strains was not significantly different between the endoscopic findings; 50% in normal endoscopy, 60% in non-ulcer dyspepsia and 59% in peptic ulcer disease. However, cytotoxic strains were more common in subjects with severe histological gastritis than in those with normal mucosa or mild gastritis (66% vs 30%, p<0.01). Similarly, the prevalence of cytotoxic strains was also higher in subjects with active gastritis than in those without (64% vs 23%, p<0.01). CONCLUSIONS: McCoy cells are more sensitive than HeLa cells for detecting Helicobacter pylori cytotoxicity in vitro. There is an association between cytotoxic strains and the severity and activity of histological gastritis.
Adolescent↗